The Experts – REVIVE Hub

About
The Experts
Webinars
Resources
Forums
Talk to an expert
JOIN US
My account
- Logout

Loading...

The Experts

Our team of experts (more coming soon)

You are here:Home-The Experts

Jesús Rodríguez-Baño — Jesús Rodríguez-Baño
Professor of Medicine
University of Seville

Michael Barbachyn — Michael Barbachyn
Professor, Brummel Chair in Organic Chemistry
Calvin College

Greg Basarab — Greg Basarab
Principal Research Officer and Associate Director
University of Cape Town

Helen W Boucher — Helen W Boucher
Professor of Medicine, Director, Infectious Disease Fellowship Program
Tufts Medical Center

Pamela Brown — Pamela Brown
Consultant
Antibacterial Drug Discovery and Medicinal Chemistry

Karen Bush — Karen Bush
Professor of Practice
Department of Biology, Indiana University

Ryan Cirz — Ryan Cirz
Vice president, Infectious Disease Research and Head, Postdoctoral Program
Achaogen

Patrice Courvalin — Patrice Courvalin
Emeritus Professor
Department of Microbiology, Institut Pasteur

Mike Dawson — Mike Dawson
Director
Mike Dawson Antimicrobial Research Consultancy

George L Drusano — George L Drusano
Director
Institute for Therapeutic Innovation, University of Florida

Jacques Dumas — Jacques Dumas
Chief Scientific Officer
Tetraphase Pharmaceuticals

Barry I Eisenstein — Barry I Eisenstein
Chair, Scientific Advisory Board
CARB-X

Domingo Gargallo-Viola — Domingo Gargallo-Viola
Founder and Chief Scientific Officer
ABAC Therapeutics

Olga Genilloud — Olga Genilloud
Scientific Director
Fundación MEDINA

Mark J Goldberger — Mark J Goldberger
Independant Consultant

Bob Hancock — Bob Hancock
Killam Professor of Microbiology and Immunology
The University of British Columbia

Stephen Hawser — Stephen Hawser
Chief Executive Officer
IHMA Europe Sàrl

Deborah Hung — Deborah Hung
Associate Professor
Department of Molecular Biology, Massachusetts General Hospital

Khalid Islam — Khalid Islam
Owner
Life Sciences Management GmbH

Nachum Kaplan — Nachum Kaplan
Chief Scientific Officer
Nobelex Biotech

Jennifer Leeds — Jennifer Leeds
Executive Director, Head of Antibacterial Discovery
Novartis Institutes for Biomedical Research

Sergio Lociuro — Sergio Lociuro
Chief Scientific Officer
BioVersys AG

Stefan Miller — Stefan Miller
Scientific Advisor
Lysando

Malcolm Page — Malcolm Page
Formerly Roche, Switzerland

Antonio Perez — Antonio Perez
Senior Consultant for Drug Development

David Pompliano — David Pompliano
Founding Chief Scientific Officer
Lodo Therapeutics

Michael Pucci — Michael Pucci
Executive Director, Early Drug Discovery
Spero Therapeutics

Céline Pulcini — Céline Pulcini
Professor, Infectious Diseases
Nancy University Hospital

Hans-Georg Sahl — Hans-Georg Sahl
Emeritus Professor
University of Bonn

Sameeh M Salama — Sameeh M Salama
Vice President of Business Development
Fedora Pharmaceuticals and Brass Dome Ventures

William Shafer — William Shafer
Professor of Microbiology and Immunology
Emory University School of Medicine

Karen J Shaw — Karen J Shaw
Chief Scientific Officer
Amplyx Pharmaceuticals

David Shlaes — David Shlaes
Former Director, Anti-Infectives Consulting
Former Professor of Medicine, Case Western Reserve University

Lynn L Silver — Lynn L Silver
LL Silver Consulting

Jared A Silverman — Jared A Silverman
Head of Translational Discovery
Bill & Melinda Gates Medical Research Institute

Joyce Sutcliffe — Joyce Sutcliffe
Independent Antibacterial Consultant

Glenn S Tillotson — Glenn S Tillotson
Partner
GST Micro

Paul M Tulkens — Paul M Tulkens
Emeritus Professor
Université catholique de Louvain

Peter Warn — Peter Warn
Senior Vice President, Anti-infective Discovery
Evotec

Mark Wilcox — Mark Wilcox
Consultant Microbiologist and Head of Research and Development in Microbiology
Leeds Teaching Hospitals

Share

Facebook Twitter Linkedin Reddit Email

REVIVE Hub

REVIVE is a space for everybody with an interest in antimicrobial R&D.

Launched in 2016 by the WHO and DNDi, the Global Antibiotic Research & Development Partnership (GARDP) aims to develop and deliver new treatments for bacterial infections where drug resistance is present or emerging, or for which inadequate treatment exists, while endeavouring to ensure sustainable access. GARDP is currently operating within DNDi, which provides its governance.

Popular forum topics

Immunomodulators
Medical need and priorities
Vitamin C in treatment of bacterial sepsis
In vitro models

Latest forum posts

Setting Up A 'Support' Service in Anti-Infectives
The commercial model
We would like to receive your feedback
Specialized training programmes/courses in antimicrobial R&D

CONNECT

Facebook
Twitter
Instagram
LinkedIn
YouTube
RSS
Events

GARDP
DNDi

© All Rights Reserved

Terms of Use | Privacy Policy | Acceptable Use Policy | Cookie Policy

This website uses cookies to ensure you get the best experience on our website. Read our cookie policyGOT IT!